KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Return on Sales (2018 - 2025)

Historic Return on Sales for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to 0.1%.

  • Adaptive Biotechnologies' Return on Sales rose 7900.0% to 0.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.31%, marking a year-over-year increase of 7900.0%. This contributed to the annual value of 0.89% for FY2024, which is 4300.0% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Return on Sales stood at 0.1% for Q3 2025, which was up 7900.0% from 0.43% recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Return on Sales peaked at 0.1% during Q3 2025, and registered a low of 6.21% during Q2 2023.
  • Over the past 5 years, Adaptive Biotechnologies' median Return on Sales value was 1.14% (recorded in 2024), while the average stood at 1.31%.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Return on Sales plummeted by -50200bps in 2023, and later skyrocketed by 51400bps in 2024.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Return on Sales stood at 1.62% in 2021, then soared by 55bps to 0.73% in 2022, then crashed by -108bps to 1.52% in 2023, then surged by 53bps to 0.71% in 2024, then soared by 114bps to 0.1% in 2025.
  • Its Return on Sales was 0.1% in Q3 2025, compared to 0.43% in Q2 2025 and 0.57% in Q1 2025.